Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2003
10/29/2003EP1355668A1 Use of il-18 inhibitors for the treatment and/or prevention of heart disease
10/29/2003EP1355665A2 Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid
10/29/2003EP1355664A2 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
10/29/2003EP1355660A2 Therapeutic modulation of the tumor inflammatory response
10/29/2003EP1355653A2 Stimulation of thymus for vaccination development
10/29/2003EP1355652A2 Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders
10/29/2003EP1355651A2 Treatment of diabetes mellitus using vardenafil
10/29/2003EP1355644A2 The use of substituted azetidinone compounds for the treatment of sitosterolemia
10/29/2003EP1355639A2 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
10/29/2003EP1355633A1 New film coating
10/29/2003EP1355631A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
10/29/2003EP1355628A2 Stabilised polymeric aerosols for pulmonary gene delivery
10/29/2003EP1355588A2 Delivery of therapeutic capable agents
10/29/2003EP1355530A2 Method for the detection of prions in a sample
10/29/2003EP1214056B1 Topical suspension formulations containing ciprofloxacin and dexamethasone
10/29/2003EP1140047B1 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
10/29/2003EP1082129B1 Method for the treatment of fertility disorders
10/29/2003EP1017370B1 MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
10/29/2003EP1007093B1 Treatment of disorders using interleukin-9
10/29/2003EP0994711B1 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
10/29/2003EP0951553B1 Adenovirus e4 proteins for inducing cell death
10/29/2003EP0594803B1 Composition for reducing side-effects of a drug
10/29/2003CN1452719A Method for identifying combinations of drugs
10/29/2003CN1452627A 3'-prodrugs of 2'-deoxy-beta-L-nucleosides
10/29/2003CN1452622A Piperzine devivs.
10/29/2003CN1452497A Combinations of SSRI and estrogenic agents
10/29/2003CN1452494A Use of secretin-receptorl igands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)
10/29/2003CN1452487A Antimicrobial composition and mthod for producing same
10/29/2003CN1452478A Pre-formed sheet devices suitable for topical application
10/29/2003CA2445913A1 Method of treatment
10/28/2003US6639078 Assays for ligands for nuclear receptors
10/28/2003US6639076 Such as 2-(2-amino-2-methylpropanoylamino)-n-(1-(2-oxo-1-phenyl-2-pyrrolidinylethyl -4-yl)-4-phenylbutanamide
10/28/2003US6639051 Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
10/28/2003US6638981 Topical compositions and methods for treating pain
10/28/2003US6638971 Cocoa extract compounds and methods for making and using the same
10/28/2003US6638969 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
10/28/2003US6638967 Pyrrole, furan, thiofuran and phenyl derivatives; inhibition of histamine H3 receptor activity; for example, 1-((4-(4-Pyrrolidin-1-ylmethyl-phenyl)-thien-2-yl)methyl)-pyrrolidine
10/28/2003US6638966 Use of melatonin analogues for induction of general anesthesia
10/28/2003US6638963 Administering melatonin, a melatonin agonist or compound that increases melatonin production
10/28/2003US6638957 Inhibition of 1-deoxy-D-xylulose-5-phosphate metabolic pathway
10/28/2003US6638949 Angiogenesis inhibitor is selective, such as a fumagillol derivative like 0-chloroacetylcarbamoyl-Fumagillol, thalidomide, or a selective drug having more than one activity, such as minocycline or penicilliamine which also
10/28/2003US6638926 Pyrazole compounds useful as protein kinase inhibitors
10/28/2003US6638920 Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
10/28/2003US6638913 Concentrated injection and infusion solution for intravenous administration
10/28/2003US6638767 Methods for delivering compounds into a cell
10/28/2003US6638747 Isolated polypeptide having specified amino acid sequence
10/28/2003US6638727 Intraductally administering an estrogen activity modulator
10/28/2003US6638543 Comprising an admixture of a natural inhibitor of epidermal growth factor receptor (EGFR) activation or a derivative or analog and a dermatological carrier; antipeeling agents; genistein and other isoflavones and other plant extracts
10/28/2003US6638539 Trace elements
10/28/2003US6638532 Tetracycline—doxycycline antibiotic composition
10/28/2003US6638522 Carrier comprising solubilizing amount of propylene glycol monoester of C6-C18 fatty acid and nonionic surfactant
10/28/2003US6638514 Immunogenic attenuated dengue viruses produced by serial passage in primary dog kidney cells
10/28/2003US6638495 Stabilized preparation for use in metered dose inhalers
10/28/2003CA2283939C Non-antigenic branched polymer conjugates
10/28/2003CA2213099C S-(+)-adenosylmethionine and 3'-azido-2',3'-dideoxy-nucleoside complexes as potent inhibitors of hiv-replication
10/23/2003WO2003087841A2 An ephrin-b receptor protein involved in carcinoma
10/23/2003WO2003087840A2 Protein involved in cancer
10/23/2003WO2003087832A2 Diagnosis of carcinoma using raigi polypeptides
10/23/2003WO2003087818A2 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction
10/23/2003WO2003087815A2 Method for the identification of inhibitors of the binding of are-containing mrn a and an hur protein
10/23/2003WO2003087406A1 Diagnostic and therapeutic use of an atp-binding cassette gene and protein for neurodegenerative diseases
10/23/2003WO2003087399A1 Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
10/23/2003WO2003087380A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use
10/23/2003WO2003087374A1 Derivatives of the il-2 receptor gamma chain, their production and use.
10/23/2003WO2003087356A2 Helicokinin-receptor from insects
10/23/2003WO2003087347A1 Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
10/23/2003WO2003087345A2 Stimulation of nerve cell regeneration
10/23/2003WO2003087338A2 Her-2 receptor tyrosine kinase molecules and uses thereof
10/23/2003WO2003087333A2 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
10/23/2003WO2003087308A2 Use of interleukin-24 to treat ovarian cancer
10/23/2003WO2003087307A2 Use of interleukin-19 to treat cervical cancer
10/23/2003WO2003087303A2 Tissue composites and uses thereof
10/23/2003WO2003087164A1 Iron dextrin compounds for the treatment of iron deficiency anaemia
10/23/2003WO2003087121A1 Branched polyamine steroid derivatives
10/23/2003WO2003087097A1 Medicaments containing betamimetic drugs and a novel anticholinesterase drug
10/23/2003WO2003087096A1 Novel ester hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, methods for the production thereof, and use thereof as a medicament
10/23/2003WO2003087073A1 Estrogen receptor modulators
10/23/2003WO2003087049A2 Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
10/23/2003WO2003086472A1 Drugs to be used in gene therapy for recessively transmitted genetic disease
10/23/2003WO2003086467A1 Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
10/23/2003WO2003086466A1 Novel thrombomodulin expression promoters
10/23/2003WO2003086465A1 Drugs for myopia correction surgery
10/23/2003WO2003086461A2 Use of substances for treating tumors
10/23/2003WO2003086452A2 Methods of enhancing lysosomal storage disease therapy
10/23/2003WO2003086448A1 Use of c5a receptor antagonist in the treatment of fibrosis
10/23/2003WO2003086440A1 Novel use of the extract of processed ginseng and saponin isolated therefrom
10/23/2003WO2003086424A1 Pharmaceutical composition comprising arsenite for the treatment of malignancy
10/23/2003WO2003086423A1 Low-dose potassium supplementation for the prevention and treatment of hypertension
10/23/2003WO2003086419A1 Antibiotic/benzoyl peroxide dispenser
10/23/2003WO2003086418A1 Methods for the treatment of cancer
10/23/2003WO2003086415A1 Method for inhibiting bone resorption with an alendronate and vitamin d formulation
10/23/2003WO2003086413A1 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
10/23/2003WO2003086410A1 Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
10/23/2003WO2003086404A1 Fused quinoxaline derivatives as inhibitors of akt activity
10/23/2003WO2003086394A1 Inhibitors of akt activity
10/23/2003WO2003086386A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures
10/23/2003WO2003086382A1 Tnp-470 polymer conjugates and use thereof
10/23/2003WO2003086374A1 Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
10/23/2003WO2003086373A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
10/23/2003WO2003086372A2 Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction
1 ... 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 ... 1151